Chondroitin may help improve symptoms of osteoarthritis when used with glucosamine and manganese ascorbate; however, the American College of Rheumatology doesn't recommend substituting chondroitin for traditional treatment.
Chondroitin sulfate is a natural substance found in the body. It prevents other body enzymes from degrading the building blocks of joint cartilage.
People who use these nutritional supplements hope that they will relieve the pain of osteoarthritis, and perhaps even repair or restore the joint cartilage.
But there is no proof that either substance, taken singly or in combination, will actually slow the degenerative process or restore cartilage in arthritic joints.
Evidence suggests that chondroitin may relieve symptoms of osteoarthritis more effectively than placebo, and that results endure for at least 1 year. Evidence that chondroitin can alter the natural history of osteoarthritis by slowing progressive joint damage is weaker.
Showing posts with label Arthritis. Show all posts
Showing posts with label Arthritis. Show all posts
Wednesday, 20 February 2008
Study says that Glucosamine doesn't help with Osteoarthritis
A new research has reveled that glucosamine sulfate, a dietary supplement used as a treatment for osteoarthritis, had absolutely no impact on reducing pain and inflammation of hip arthritis.
Arthritis means inflammation of the joints. Osteoarthritis (OA) is the most common form of arthritis in the UK. OA mainly affects the joint cartilage and the bone tissue next to the cartilage.
The results of the study revealed that glucosamine sulfate does not appear to treat hip arthritis and that the difference between glucosamine and placebo group in treating mild to moderate hip arthritis were very small.
Osteoarthritis commonly affects the hands, feet, spine, and large weight-bearing joints, such as the hips and knees. Most cases of osteoarthritis have no known cause and are referred to as primary osteoarthritis. When the cause of the osteoarthritis is known, the condition is referred to as secondary osteoarthritis.
Arthritis means inflammation of the joints. Osteoarthritis (OA) is the most common form of arthritis in the UK. OA mainly affects the joint cartilage and the bone tissue next to the cartilage.
The results of the study revealed that glucosamine sulfate does not appear to treat hip arthritis and that the difference between glucosamine and placebo group in treating mild to moderate hip arthritis were very small.
Osteoarthritis commonly affects the hands, feet, spine, and large weight-bearing joints, such as the hips and knees. Most cases of osteoarthritis have no known cause and are referred to as primary osteoarthritis. When the cause of the osteoarthritis is known, the condition is referred to as secondary osteoarthritis.
Monday, 18 February 2008
Glaxo Pay $44m in Rheumatoid Arthritis Treatment deal
GlaxoSmithKline have agreed to contribute$44 million plus royalties to EUSA Pharma Inc for the worldwide rights to the company's pre-clinical antibody aimed at treating lymphoma and rheumatoid arthritis.
Rheumatoid arthritis is the most common type of inflammatory arthritis, affecting about one in 100 people.
Rheumatoid arthritis occurs when the body's defence mechanisms go into action when there's no threat and start attacking the joints and sometimes other parts of the body. It's not yet known why the immune system acts in this way in some people.
Glaxo agreed to fund future development, production and marketing of the antibody as part of the licensing deal.
The human antibody, called OP-R003, targets a protein called interleukin-6. EUSA has previously sought to develop it as a treatment for rheumatoid arthritis and lymphoma.
Fully human therapeutic antibodies avoid the use of animal material to reduce the risk of any adverse patient reactions. A number of companies are looking at treatments involving the interleukin-6 protein.
Rheumatoid arthritis is the most common type of inflammatory arthritis, affecting about one in 100 people.
Rheumatoid arthritis occurs when the body's defence mechanisms go into action when there's no threat and start attacking the joints and sometimes other parts of the body. It's not yet known why the immune system acts in this way in some people.
Glaxo agreed to fund future development, production and marketing of the antibody as part of the licensing deal.
The human antibody, called OP-R003, targets a protein called interleukin-6. EUSA has previously sought to develop it as a treatment for rheumatoid arthritis and lymphoma.
Fully human therapeutic antibodies avoid the use of animal material to reduce the risk of any adverse patient reactions. A number of companies are looking at treatments involving the interleukin-6 protein.
Pfizer funds massive drug trial for Arthritis
THOUSANDS OF arthritis sufferers in Scotland have been asked to take part in drugs trials that could improve the lives of millions with the disease. The three-year trial, which will involve 400 GP practices and 16,000 patients, has been given £24 million by pharmaceutical giant Pfizer to work out which painkillers offer the best relief with the fewest side-effects.
Arthritis is a common condition that affects an estimated 8 million people in the UK. There are about 200 forms of arthritis affecting young and old alike and the symptoms can affect many parts of the body. Most people with arthritis find that being armed with information helps them make positive changes to their lives.
Currently, chronic sufferers are forced to take a toxic cocktail of drugs which have a range of health implications, including increasing the risk of heart disease in older people by 70%.
The kind of arthritis , its severity and peoples own wishes will all influence what treatment is provided.
Arthritis sufferers have cautiously welcomed the news, in the knowledge that a cure is not yet in sight. The tests will rely on Scotland's world-leading health statistics system, which detected a 17% drop in admission for heart problems after the smoking ban came into force.
Arthritis is a common condition that affects an estimated 8 million people in the UK. There are about 200 forms of arthritis affecting young and old alike and the symptoms can affect many parts of the body. Most people with arthritis find that being armed with information helps them make positive changes to their lives.
Currently, chronic sufferers are forced to take a toxic cocktail of drugs which have a range of health implications, including increasing the risk of heart disease in older people by 70%.
The kind of arthritis , its severity and peoples own wishes will all influence what treatment is provided.
Arthritis sufferers have cautiously welcomed the news, in the knowledge that a cure is not yet in sight. The tests will rely on Scotland's world-leading health statistics system, which detected a 17% drop in admission for heart problems after the smoking ban came into force.
Thursday, 7 February 2008
Overuse of NSAIDS
Patients who took both over-the-counter and prescription nonsteroidal anti-inflammatory drugs (NSAIDs) had reduced pain from arthritis during daily activities, but this practice may increase complications, according to the results of a study reported in the January 31 Online First issue and will appear in the February 15 issue of Arthritis Care & Research. See Medscape
"Inadequate prescription therapy pain management, lack of doctor-patient communication about over-the-counter (OTC) medications, and easy accessibility of OTC medications may contribute to patients using more than 1 medication to manage pain," write Stacey H. Kovac, PhD, from Durham Veterans Administration Medical Center and Duke University in Durham, North Carolina.
It is well established that taking multiple nonsteroidal antiinflammatory drugs (NSAIDs) can lead to serious gastrointestinal problems. Little is known about whether use of more than 1 NSAID (i.e., dual use) is related to patient self-reported outcomes.
Patients may self-manage their pain to improve their daily activities by taking more than 1 NSAID," the study authors write. "However, by attempting to obtain symptom relief, patients may be putting themselves at risk for complications. Providers are likely unaware of patients' risk
"Inadequate prescription therapy pain management, lack of doctor-patient communication about over-the-counter (OTC) medications, and easy accessibility of OTC medications may contribute to patients using more than 1 medication to manage pain," write Stacey H. Kovac, PhD, from Durham Veterans Administration Medical Center and Duke University in Durham, North Carolina.
It is well established that taking multiple nonsteroidal antiinflammatory drugs (NSAIDs) can lead to serious gastrointestinal problems. Little is known about whether use of more than 1 NSAID (i.e., dual use) is related to patient self-reported outcomes.
Patients may self-manage their pain to improve their daily activities by taking more than 1 NSAID," the study authors write. "However, by attempting to obtain symptom relief, patients may be putting themselves at risk for complications. Providers are likely unaware of patients' risk
Subscribe to:
Posts (Atom)